

Development and Validation of Methods for Detection of Aflatoxin-Lysine Adduct in Dried Blood Spot Samples

Jia-Sheng Wang Department of Environmental Health Science University of Georgia






Aflatoxins

- A group of potent mycotoxins produced mainly by *Aspergillus flavus* and *A. parasiticus;*
- Widespread food contaminants, especially for corn & corn products, peanuts & other groundnuts, and rice;
- Human aflatoxicosis and hepatocellular carcinoma;
- Immunosuppressors;
- Anti-nutritional agents;
- Inhibition of children growth and development.






Metabolic Pathways of AFB₁





Biomarkers



Exposure biomarkers

Effect biomarkers





Original Goals

- To establish and validate methods for measuring major aflatoxin biomarkers in human dried blood spot (DBS) samples;
- To support needs of aflatoxin exposure assessment in USAID supported Peanut and Mycotoxin Innovation Laboratory (PMIL) and Nutrition Innovation Laboratory (NIL) research projects.





Working Hypothesis

 Levels of AFB₁-lysine adduct in human blood or DBS samples are correlated to dietary aflatoxin exposure and will be a reliable effective biological response indicator for aflatoxin-linked adverse health effects in high-risk human populations.





Background Information

- DBS sampling technique was first developed to screen newborn babies for the genetic metabolic disorder, phenylketonuria.
- DBS has been applied to nutritional supplement studies and pharmacokinetics' studies during new drug development.
- DBS has been used for various "omics" studies.
- DBS has been proposed to use for HIV and HCV research and various environmental exposure studies.





Advantages of DBS Technique

- Less invasive;
- Uses smaller blood volumes;
- Utilizes simple storage methods;
- Minimizes shipping expenses;
- Offers convenient sampling;
- Reduces risk of blood-borne pathogens such as HIV, etc.





Regular methods Dried Blood Spots ~ 3ml Blood 5 x 50 µl Blood 150µl serum aliquot





Challenges

- Hold enough mycotoxin or test target?
- Sensitivity?
- Specificity?
- Accuracy?
- Platform analysis for large quantity of samples?
- Acceptation?





Phase 1 Objectives

- To compare capacity of DBS cards from different commercial sources for holding the whole blood, serum/plasma, and to optimize the elution procedure for recovery of all materials in DBS cards.
- To establish methods to measure concentrations of total proteins and albumin in diluted micro-volume eluting solutions and to optimize conditions of enzyme digestion to release aflatoxin-bound lysine adduct from the albumin.





Phase 1 Objectives (continued)

- To develop method for concentration and purification of aflatoxin-lysine adduct in digests for instrument analysis;
- To determine analytical chemistry parameters, such as accuracy, precision, sensitivity (limit of detection), reproducibility, and recovery for the method.





Commercial DBS Card Comparison

Untreated Cards

- Ahlstrom 226
- Munktell TFN
- GE Whatman DMPK C 31ETF base paper
- GE Whatman 903

Treated Cards

- GE Whatman DMPK A (FTA) 31ETF base paper 4 additives, for 'protection' of genetic material
- GE Whatman DMPK B (FTA Elute) 903 base paper 1 additive, will denature proteins





Main Supplies







903 TM Protein Saver		Whatman 903TM	LOT W113 6938012
For Research Use Only Not for use in diagnostic proc	edures	A MAN	A A A
Tuck Cover Here		Tuck Co	ver Hore
Name		Name	
Date		Date	
CALIFORNIA AND A STREET, SALES	A PERSONAL PROPERTY	Service and the service	












Unsatisfactory Specimens



Supersaturated



Specimen Not Dried Before Mailing




Serum Rings




Clotted or Layered







Quantity Insufficient for Testing



Scratched or Abraded




Diluted, Discolored, or Contaminated



No Blood






















Manual




Selection of DBS Extraction System





Lab Procedure







Method Developed

- Sample collection : \leq 50 µl blood in DBS card
- Washing Solution: Triton-100-PBS and rebuild the sample solution;
- Determination of albumin and total protein concentrations;
- Pronase digestion, solid-phase concentration and purification;
- HPLC-fluorescent detection, and MS confirmation;
- Limit of detection: 20 fg/mg albumin;
- Recovery: averaged 75% for various spiked concentrations.





Elution & Washing Efficiency

Total Protein	(µg)
---------------	------

	Serum	Dilute to 1.5ml	Serum Spot Eluent			
			Wash 1	Wash 2	Wash 3	Sum
20µl	1365.61	1409.63	1416.97	117.10	-56.75	1534.07
40µl	2731.23	2644.29	2206.00	322.65	-8.86	2528.66
60µl	4096.84	4131.43	2964.46	490.41	4.55	3459.42

Triplicate experiments





Elution & Washing Efficiency


Total Albumin (μg)						
	Serum Dilute to 1.5ml Serum Spot Eluant					
			Wash 1	Wash 2	Wash 3	Sum
20ul	884.13	410.00	649.17	-11.67	-77.50	649.17
40ul	1768.27	1211.25	1606.67	77.50	-64.58	1684.17
60ul	2652.40	2205.00	2575.83	163.75	-49.17	2739.58

Triplicate experiments






Phase 2A: Animal Validation Studies






DBS samples from AFB₁-dosed animal blood

Whole blood DBS sample from high dose treated animals



Whole blood DBS sample from low dose treated animals








4111

NAL DE

HPLC chromatograph of AFB₁-treated rat DBS





Single dose

	2h	24hr	3d	5d	7d
Control	0.02±0.00	0.02±0.00	0.02±0.00	0.02±0.00	0.02±0.01
25µg/kg	16.48±2.58	5.62±0.42	5.90±1.02	2.83±0.16	1.34±0.16
75µg/kg	54.8±0.53	12.77±1.68	15.11±2.49	8.71±2.03	5.19±0.79
225µg/kg	143.98±20.45	96.19±10.67	80.72±5.80	66.63±16.91	36.18±7.57

N=6

Repeated Dose

Dose (µg/kg)	AFB-Lys (ng/mg alb.)						
Dose (µg/kg)	week 1	week 2	week 3	week 4	week 5		
0	0.02±0.00	0.02±0.00	0.03±0.01	0.02±0.01	0.02±0.00		
5	0.17±0.01	0.27±0.01	0.30±0.03	0.38±0.02	0.41±0.03		
10	0.51±0.02	0.76±0.06	0.90±0.06	0.98±0.03	1.04±0.07		
25	1.44±0.11	2.01±0.13	2.09±0.08	2.56±0.16	2.79±0.16		
75	2.02±0.13	2.76±0.16	2.76±0.28	2.64±0.11	2.50±0.13		

N=6





Single Dose


0 400 800 0 400 800 0 400 800 1 1 1 1 1 1 1 1 1 2 h 7d 24h 3d 5d superpose 150 o time 100 2 h o DBS 24h o 3d o 5d 7d o ο. 50 0 Ϋ́Τ Т П Т 11 11 0 400 800 0 400 800 0 400 800 group

DBS ~ group + time





Single Dose




Scatter plots (left) and Bland–Altman plots (right) for paired serum and DBS specimens measured by HPLC. In scatter plots, solid line = linear regression. In Bland–Altman plots, center line indicates mean difference between serum and DBS measures; upper and lower lines indicate the 95% confidence interval.





Repeated Doses




DBS ~ Group + Time





Repeated Dose



Scatter plots (left) and Bland–Altman plots (right) for paired serum and DBS specimens measured by HPLC. In scatter plots, solid line = linear regression. In Bland–Altman plots, center line indicates mean difference between serum and DBS measures; upper and lower lines indicate the 95% confidence interval.






Phase 2B. Human Validation Study

Dietary aflatoxin exposure	Low	Middle	High
Participant numbers	12	12	12
Detection rate (%)	50 (6/12)	58.3 (7/12)	100 (12/12)
Median level of AFB-lysine adduct (pg/mg albumin)	3.92	12.18	136.26
Range of AFB-lysine adduct (pg/mg albumin)	0-4.78	0-24.64	61.49-992.42







Human Validation Study

Scatter plots (left) and Bland–Altman plots (right) for paired human serum and DBS specimens. In scatter plots, solid line = linear regression. In Bland–Altman plots, center line indicates mean difference between serum and DBS measures; upper and lower lines indicate the 95% confidence interval.





Phase 3. Application Study

Use of DBS samples collected from USAID NIL conducted Aflatoxin Birth Cohort Study in Nepal to assess mother/children aflatoxin exposure and its correlation with adverse growth/development effects.






AFB-Lys Adduct Levels in Five Batches of DBS Samples from Nepal Birth Cohort Study

Parameter	Batch 1	Batch 2	Batch 3	Batch 4	Batch 5
AFB-Lys Adduct (pg/mg albumin)					
Number	171	128	320	222	222
Detection rate (%)	98.83	96.88	100	100	100
Median	1.65	1.21	2.99	8.64	15.68
Geometric Mean	4.24	1.77	2.92	8.94	14.71
95% CI	3.92 –	1.51 –	2.76 -	8.49 -	13.88-
	4.57	2.04	3.07	9.42	15.88
Minimal	0.40	0.20	0.43	3.51	2.92
Maximal	147.32	14.10	75.31	40.25	44.85





Distribution of AFB-Lys adduct Levels in DBS Samples of Nepal Birth Cohort







Outcomes and Impacts

- Highly innovative and significant;
- Meet urgent needs;
- Fill the research gaps;
- Generate data for understanding the relationship between biological response and aflatoxin exposure.
- Significantly beneficial for the health-effect assessment of children as a result of long-term exposure to aflatoxins in developing world.





Acknowledgement

- USAID Feed the Future Program Nutrition and Peanut/Mycotoxin Innovation Laboratories
- University of Georgia
 - Lili Tang, Co-PI; Kathy S. Xue; Wenjie Cai
- Tufts University
 - Drs. Patrick Webb, Shibani Ghosh, Johanna Y. Andrews Trevino from Nutrition Innovation Laboratory
- Collaborators from NIL and PMIL Focused Countries
 - Nepal site
 - Uganda site

